Bimizza® – A low cost1-3, bioequivalent alternative to Mercilon®4

  • Bimizza® is a monophasic combined oral contraceptive pill which contains 150mcg desogestrel and 20mcg ethinylestradiol3
  • Bimizza® contains the same active ingredients and is bioequivalent to Mercilon®, therefore, following appropriate patient assessment and review, it may be prescribed in place of Mercilon®3–5
  • Each pack of Bimizza® contains 3 x blister strips of 21 tablets for 3 cycles of contraceptive cover6

Please refer to the full Summary of Product Characteristics (SmPC) before prescribing.

Summary of Product Characteristics and Patient Information Leaflet
Summary of Product Characteristics:

Patient Information Leaflet:

Additional Prescriber Resources
Whether your patient is starting the pill for the first time, or you are talking to her about changing from her current brand of contraceptive to Bimizza®, it can be useful to have information and materials to hand to counsel patients. The following assets can be downloaded/edited at your discretion for use during a consultation:

The full NICE Clinical Knowledge Summary for contraceptive prescribing for combined oral contraceptives, including UK Medical Eligibility Criteria may be found here.


  1. Data on File: Contraceptives Cost Saving Data. Feb 2019;
  2. MIMS. Mercilon (Merck Sharp & Dohme Ltd). Available at: (accessed July 2020);
  3. Morningside Healthcare Ltd. Bimizza® PI. May 2020. BIM/PI/27333-0520;
  4. MHRA. UK PAR Bimizza 150 microgram/20 microgram tablets. February 2015. Available at: (accessed July 2020);
  5. Merck Sharp & Dohme Ltd. Mercilon Tablets. Summary of Product Characteristics. December 2018. Available at: (accessed July 2020);
  6. MIMS. Bimizza. Available at: (accessed July 2020).

Mercilon® chosen as a comparator as it is the license reference product for Bimizza®.4